98%
921
2 minutes
20
Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive subtype of lymphoma, and accurate survival prediction is crucial for treatment decisions. This study aims to develop a robust survival prediction strategy to integrate various risk factors effectively, including clinical risk factors and Deauville scores in positron-emission tomography/computed tomography at different treatment stages using a deep-learning-based approach. We conduct a multi-institutional study on 604 DLBCL patients' clinical data and validate the model on 220 patients from an independent institution. We propose a survival prediction model using transformer architecture and a categorical-feature-embedding technique that can handle high-dimensional and categorical data. Comparison with deep-learning survival models such as DeepSurv, CoxTime, and CoxCC based on the concordance index (C-index) and the mean absolute error (MAE) demonstrates that the categorical features obtained using transformers improved the MAE and the C-index. The proposed model outperforms the best-performing existing method by approximately 185 days in terms of the MAE for survival time estimation on the testing set. Using the Deauville score obtained during treatment resulted in a 0.02 improvement in the C-index and a 53.71-day improvement in the MAE, highlighting its prognostic importance. Our deep-learning model could improve survival prediction accuracy and treatment personalization for DLBCL patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137756 | PMC |
http://dx.doi.org/10.3390/healthcare11081171 | DOI Listing |
Clin Transl Oncol
September 2025
Spanish Society of Medical Oncology (SEOM) Thrombosis and Cancer Group, Madrid, Spain.
Purpose: To determine the real-world incidence and predictive factors for venous and arterial thromboembolic events (VTE/AT) in ovarian cancer patients treated with poly-(ADP-ribose) polymerase inhibitors (iPARP).
Methods/patients: A multicenter retrospective study involving 329 ovarian cancer patients who initiated iPARP treatment between January 2015 and December 2022. The primary outcome was the incidence of VTE/AT.
Gastric Cancer
September 2025
Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Background: Immune checkpoint inhibitors (ICIs) play a pivotal role in the treatment of advanced gastric cancer (GC). However, the biomarkers used to predict ICI efficacy are limited due to their reliance on single or static tumor characteristics. This study aims to develop a machine learning (ML) model that incorporates dynamic changes in clinlabomics data to optimize the predictive accuracy of ICI efficacy.
View Article and Find Full Text PDFPituitary
September 2025
Facoltà Di Medicina E Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
Introduction: Pituitary adenomas (PAs) are generally benign neoplasms, though in rare cases may exhibit aggressive behavior. In 2024, the PANOMEN-3 workshop released a new clinical-pathological classification. The objective of this study was to examine the potential of the PANOMEN-3 classification to predict prognosis of PAs and guide treatment in our single center cohort of patients with PAs.
View Article and Find Full Text PDFNutr Clin Pract
September 2025
Nutrition Department, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Background: Early diagnosis of malnutrition is essential for rapid decision-making regarding nutrition care to improve patient outcomes. We aimed to evaluate the prevalence of malnutrition using the Global Leadership Initiative on Malnutrition (GLIM) criteria and to assess the association of GLIM with 1-year mortality and length of hospital stay (LOS) in patients admitted to an emergency department (ED).
Methods: Prospective cohort study conducted in the ED of a university hospital.
Oncogene
September 2025
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
There are no proven therapies for metastatic or unresectable Chromophobe Renal Cell Carcinoma (ChRCC). ChRCC is characterized by high glutathione levels and hypersensitivity to ferroptosis, an iron-dependent form of cell death characterized by peroxidation of polyunsaturated fatty acids. The underlying mechanisms leading to ferroptosis hypersensitivity are unknown.
View Article and Find Full Text PDF